Early intervention with IL-17 inhibitors among patients with plaque psoriasis is associated with improved relapse and remission rates.

The atopic dermatitis market, valued at USD 9.33 billion in 2024, is projected to grow at a CAGR of 15.10%, reaching USD 38.07 billion by 2034. Key drivers include increasing prevalence, FDA approvals ...

The likelihood of reduced quality of life and high symptom burden in patients with psoriasis was similar across those with low, medium, and high BSA.

IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation, joint pain, and ...

Introducing lebrikizumab for severe atopic dermatitis in Italy may result in cost savings for the national health system, a ...

Adult-onset Still's Disease (AOSD) is a rare, systemic inflammatory disorder characterized by high fevers, rashes, and arthritis, impacting adults wi ...

The American Academy of Dermatology has updated its guidelines for treating and managing atopic dermatitis with topical and ...

A new research paper was published in Volume 16 of Oncotarget on July 9, 2025, titled "A novel anti-human CD25 mAb with ...

Genascence’s GNSC-001 for knee osteoarthritis receives US FDA regenerative medicine advanced therapy designation: Palo Alto, California Saturday, July 19, 2025, 16:30 Hrs [IST] ...

US FDA accepts Bristol Myers Squibb’s sNDA for Sotyktu to treat adults with active psoriatic arthritis: Princeton, New Jersey Tuesday, July 22, 2025, 12:00 Hrs [IST] Bristol Mye ...

STUTTGART, Germany I July 21, 2025 I La Merie Publishing released its newest product entitled: TL1A Inhibitors & DR3 Antagonists: a Competitor Analysis ...

A deft uveitis diagnosis can help reveal underlying systemic infections, neoplastic conditions, and other systemic illnesses.